FDA relied on proprietary company data, charges Pfizer

Share this article:
Pfizer's charge that the FDA relied on proprietary company data on its Genotropin in approving rival Sandoz' human growth hormone product Omnitrope have been denied by the agency. It said Sandoz had to establish that "Omnitrope is highly similar to Genotropin without reference to proprietary data in Pfizer's Genotropin NDA."
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.